MX2021007448A - Antagonistas. - Google Patents

Antagonistas.

Info

Publication number
MX2021007448A
MX2021007448A MX2021007448A MX2021007448A MX2021007448A MX 2021007448 A MX2021007448 A MX 2021007448A MX 2021007448 A MX2021007448 A MX 2021007448A MX 2021007448 A MX2021007448 A MX 2021007448A MX 2021007448 A MX2021007448 A MX 2021007448A
Authority
MX
Mexico
Prior art keywords
antagonists
pcsk9
antibodies
fragments
combinations
Prior art date
Application number
MX2021007448A
Other languages
English (en)
Inventor
Allan Bradley
Qi Liang
E- Chiang Lee
Li Ying Liou
Yu Hui Huang
Yen Ju Chen
Li Tzu Chen
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2021007448A publication Critical patent/MX2021007448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a antagonistas de la proproteína convertasa subtilisina kexina tipo 9 (PCSK9), tales como anticuerpos y fragmentos, así como también a procedimientos, usos y combinaciones.
MX2021007448A 2018-12-19 2019-12-18 Antagonistas. MX2021007448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820687.0A GB201820687D0 (en) 2018-12-19 2018-12-19 Antagonists
PCT/GB2019/053607 WO2020128467A2 (en) 2018-12-19 2019-12-18 Antagonists

Publications (1)

Publication Number Publication Date
MX2021007448A true MX2021007448A (es) 2021-12-10

Family

ID=65147244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007448A MX2021007448A (es) 2018-12-19 2019-12-18 Antagonistas.

Country Status (16)

Country Link
US (1) US20220049017A1 (es)
EP (1) EP3897830A2 (es)
JP (1) JP2022514703A (es)
KR (1) KR20210105396A (es)
CN (1) CN113453756A (es)
AU (1) AU2019411526A1 (es)
BR (1) BR112021011886A2 (es)
CA (1) CA3122655A1 (es)
CO (1) CO2021007653A2 (es)
GB (1) GB201820687D0 (es)
IL (1) IL283413A (es)
MA (1) MA54534A (es)
MX (1) MX2021007448A (es)
SG (1) SG11202105784WA (es)
TW (1) TW202039565A (es)
WO (1) WO2020128467A2 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731568A (en) 1995-10-13 1998-03-24 Arctic Fox, Inc. Battery heating device and method
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MX2011014008A (es) 2009-06-26 2012-06-01 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2650016A1 (en) * 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US9017678B1 (en) * 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
CN106459182B (zh) 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途

Also Published As

Publication number Publication date
EP3897830A2 (en) 2021-10-27
IL283413A (en) 2021-07-29
SG11202105784WA (en) 2021-07-29
AU2019411526A1 (en) 2021-06-17
CO2021007653A2 (es) 2021-09-30
BR112021011886A2 (pt) 2021-09-08
GB201820687D0 (en) 2019-01-30
TW202039565A (zh) 2020-11-01
KR20210105396A (ko) 2021-08-26
CN113453756A (zh) 2021-09-28
CA3122655A1 (en) 2020-06-25
JP2022514703A (ja) 2022-02-14
MA54534A (fr) 2022-03-30
US20220049017A1 (en) 2022-02-17
WO2020128467A2 (en) 2020-06-25
WO2020128467A3 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
MX2023010757A (es) Variantes de proteasa y sus usos.
MY168961A (en) Antibodies to pcsk9 and uses thereof
MY198059A (en) Anti-ox40 antibodies and their uses
PH12020551997A1 (en) Psma binding agents and uses thereof
EP4234693A3 (en) Bacillus gibsonii-clade serine proteases
MY192158A (en) Anti-pd-1 antibodies and their uses
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MY195442A (en) Anti-CD40 Antibodies and Their Uses
TR201906696T4 (tr) Pcsk9 antagoni̇stleri̇
TN2009000410A1 (en) Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP4219704A3 (en) Aprl-clade protease variants and uses thereof
EA201391157A1 (ru) Антагонисты pcsk9
IL266066A (en) Methods for preventing cardiovascular events by reducing the protein proprotein convertase subtilisin kexin 9
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
MX2023003394A (es) Variantes de proteasa y sus usos.
EA201892624A1 (ru) Растения, дающие бессемянные плоды
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2018016282A (es) Proteasas asparticas.
MX2021007448A (es) Antagonistas.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2020012214A (es) Composiciones que comprenden moléculas que se unen a la pcsk9 y métodos de uso.
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.